Acadia Pharmaceuticals (ACAD) Short term Debt (2010 - 2012)

Acadia Pharmaceuticals (ACAD) posted quarterly Short term Debt of $22000.0 for Q1 2012, down 31.25% quarter-over-quarter from $32000.0 in Q4 2011.

Analysis

Acadia Pharmaceuticals (ACAD) Short term Debt (2010 - 2012) Analysis & Trends

Acadia Pharmaceuticals' Short term Debt history runs 3 years deep, the most recent figure standing at $22000.0 for Q1 2012.

In Q1 2012, Short term Debt changed N/A year-over-year to $22000.0; the TTM figure through Mar 2012 stood at $22000.0 (changed N/A YoY), while the FY2011 annual figure was $32000.0, down 58.97% from the prior year.
Short term Debt for Q1 2012 stood at $22000.0, down from $32000.0 in the prior quarter.
The five-year high for Short term Debt was $78000.0 in Q4 2010, with the low at $22000.0 in Q1 2012.
The 3-year median for Short term Debt is $37000.0 (2011), against an average of $41800.0.
Peak annual rise in Short term Debt reached 58.97% in 2011, while the deepest fall reached 58.97% in 2011.
Acadia Pharmaceuticals' Short term Debt stood at $78000.0 in 2010, then slumped by 58.97% to $32000.0 in 2011, then plunged by 31.25% to $22000.0 in 2012.
Business Quant data shows ACAD's Short term Debt at $22000.0 in Q1 2012, $32000.0 in Q4 2011, and $37000.0 in Q3 2011.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Acadia Pharmaceuticals	4.82 Bn	3.86 Bn	279.64 Mn

Historic Data

Download Data